ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Bispecific T-cell engagers (BiTE): a review of tarlatamab in small cell lung cancer.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study.International journal of clinical oncology · 2026Article
- Safety Evaluation of Tarlatamab in SCLC: A Systematic Review and Meta-Analysis.JTO clinical and research reports · 2026Review
- Novel Organelle-Based Intracellular Immunity with Mechanistic and Therapeutic Implications.Barrier immunity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSmall-cell lung cancer remains one of the most aggressive lung malignancies, a neuroendocrine tumor with paraneoplastic features; it often grows centrally in the lung as opposed to peripheral cancers. Small-cell lung cancer (SCLC) is managed by chemotherapy and/or radiation. Due to its aggressive nature and poor prognosis, there is a need for more targeted and effective therapies; hence, the emergence of tarlatamab, a bispecific T-cell engager (BiTE), shows promise in current clinical trials. This review critically assesses the efficacy of tarlatamab in demonstrating antineoplastic activity. We also assess the safety profile, overall survival rate, progression-free survival, duration of response, and immunogenicity. METHODOLOGY: To conduct this review, a thorough preliminary search was conducted to identify key studies that evaluated the medication at specific doses among patients with small-cell lung cancer.
resultsThe positive and negative outcomes are discussed in this review, along with safety, tolerability, and performance in relapsed and refractory SLCL and biomarker insights. The adverse effects were generally manageable, most occurring during the first treatment cycle. The unique mechanism of action of tarlatamab was described with a comparative analysis with other novel monoclonal antibodies and chemotherapies for managing small-cell lung cancer (SCLC). The studies evaluated in this review are not without limitations.
conclusionTarlatamab's use must be evaluated in a more heterogeneous population with different demographics, comorbidities, and a larger patient population. The possibility of combination therapy studies should also be evaluated in future studies to increase the efficacy of tarlatamab.
Indexed as
Identifiers
40616636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.